Brexit-boost sees Germany remain Europe's pharma leader

Germany has been ranked as Europe’s most prominent pharma leader according to new data released ahead of CPhI Worldwide.

Data from the CPhI Annual Report show that Germany is ahead of other European countries in terms of API manufacturing; competitiveness; innovation; finished product manufacturing, and growth potential.

In terms of growth potential, Germany saw its rating increase by 11% from 2018, with the research’s authors attributing the shift to wider macro changes, as well as the overall strength of Europe’s pharma market. Indeed, Germany is thought to be experiencing a ‘Brexit boost’ in its medium-term growth potential, comparative with a drop from UK pharma scores.

“It is no surprise that Germany has again emerged as a global pharmaceutical leader. However, the country has further increased its score, suggesting it has consolidated its position as Europe’s top pharma industry,” said Orhan Caglayan, brand director at CPhI Worldwide.

“Significantly, in the event’s return to Frankfurt, the pharma industry in Germany is perceived as an international industry pioneer according to the latest CPhI Pharma Index. The country has the highest score in ‘API manufacturing quality’ globally, as well as the leading scores in Europe for ‘competitiveness’, ‘innovation’ and ‘finished product manufacturing’. Collectively, this points to extremely strong prospects for the German pharma industry in 2020,” Caglayan added.

The full CPhI Pharma Market Index will be made available later in the year within its 2019 Annual Industry Report.